Trials / Recruiting
RecruitingNCT07231211
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
An Open-label, Multicenter Phase I/II Clinical Study of SHR-4610 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 258 (estimated)
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open, multicenter Phase I/II clinical trial, divided into two stages: dose exploration (including dose escalation and dose extension) and efficacy extension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-4610 Injection | SHR-4610 injection in different dose. |
Timeline
- Start date
- 2025-11-20
- Primary completion
- 2026-10-01
- Completion
- 2027-12-01
- First posted
- 2025-11-17
- Last updated
- 2026-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07231211. Inclusion in this directory is not an endorsement.